<DOC>
	<DOC>NCT01221116</DOC>
	<brief_summary>Hypothesis: Treatment with levosimendan will preserve myocardial function and hemodynamics after cardiac surgery and lead to reduced stay at intensive care unit</brief_summary>
	<brief_title>Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery</brief_title>
	<detailed_description>Single center, prospective, randomized parallel-group, double-blinded study</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>EF (ejection fraction)&lt;40% renal failure, liver failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2003</verification_date>
	<keyword>coronary artery disease,</keyword>
	<keyword>aortic stenosis,</keyword>
	<keyword>heart failure</keyword>
</DOC>